Global Peptide Cancer Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2026
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
'Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026' Report highlights:
The peptide therapeutics market is currently thriving due to their various advantgaes over other available cancer therapies. The lower toxicity of peptides can be credited to both their low instance of interaction with other molecules not of interest and also their ease of metabolism into their component amino acid residues. Furthermore their ease of manufacturing has attracted several pharmaceutical companies. In addition to this, their remarkable property to cross the blood brain barrier has attracted the researchers for the development of potential peptides targeting the receptors of various cancers.
Currently, there are several peptide based drug which are available in the market and have shown positive results in the management of wide range of cancers. The increased interest of the scientists can also be justified by the rapid approval of first peptide based cancer vaccine for treatment of prostate cancer. Moreover, slews of new peptides with positive preclinical studies have entered the clinical trials and are expected to enter the market in next few years. It is expected that the drugs will show great clinical response in comparison to other available cancer therapies.
The global peptide cancer therapeutic market is going to flourish in next few years due to several favourable parameters including their high specificity, rising investments in drug discover and the increase prevalence of cancer incidences. Furthermore, the increase in colloborations and partnerships among the pharmaceutical companies for the development of novel drugs in the management of cancer is going to boost the market. Despite this, there are several challenges such as their high manufacturing cost, limited oral bioavailability and low resistance to cleavage by serum proteases which restrain their growth in market.
In terms of revenus, North America is currently holding the top position and is expected to dominate the global peptide cancer market. This is mainly attributed to the region’s potency in healthcare and a strong presence of various peptide based cancer therapeutic drug manufacturers is supporting the growth of the market in North America. Moreover, the presence of top key players such as Novartis, AstraZenecea, Teva Pharmaceuticals and Pfizer also favours the growth of this region.
On the other hand, Asia Pacific is expected to register considerable growth over the forecast period owing to high untapped opportunities, low cost of raw material, growing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in the R&D sector. Cheaper cost of raw materials and patent expiration of blockbuster drugs boosting generic market is expected to provide significant growth opportunities shortly. In coming years, the cancer therapeutics market will witness increasing adoption of novel peptide therapeutics and will contribute to a major share in the overall market.
'Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026' report provides insights into the potential application of peptide therapeutics and their mode of action in the management of different cancers. In addition to this, the report also provide data on the pricing, sales and dosage of the currently available peptide based therapeutics and the robust clinical pipeline which are expected to enter the market in next coming years. Moreover, the various key players which are indulging in research activities for the development of novel peptides is also added in the report.
'Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026' Report highlights:
- Global cancer Peptide Market Opportunity: > US$ 20 Billion By 2026
- Price, Dosage, Sales Insight On 22 Marketed Cancer Peptides
- Global Peptide Cancer Therapeutics Clinical Trials Overview by Company, Country, Indication, Phase & Formulation
- Comprehensive Clinical Insight On More Than 150 Cancer Peptides In Clinical Trials
- Comprehensive Clinical Insight On More Than 20 Cancer Peptides Available In Market
- Application of Peptides Therapeutics & Detection Methodology by Cancer
The peptide therapeutics market is currently thriving due to their various advantgaes over other available cancer therapies. The lower toxicity of peptides can be credited to both their low instance of interaction with other molecules not of interest and also their ease of metabolism into their component amino acid residues. Furthermore their ease of manufacturing has attracted several pharmaceutical companies. In addition to this, their remarkable property to cross the blood brain barrier has attracted the researchers for the development of potential peptides targeting the receptors of various cancers.
Currently, there are several peptide based drug which are available in the market and have shown positive results in the management of wide range of cancers. The increased interest of the scientists can also be justified by the rapid approval of first peptide based cancer vaccine for treatment of prostate cancer. Moreover, slews of new peptides with positive preclinical studies have entered the clinical trials and are expected to enter the market in next few years. It is expected that the drugs will show great clinical response in comparison to other available cancer therapies.
The global peptide cancer therapeutic market is going to flourish in next few years due to several favourable parameters including their high specificity, rising investments in drug discover and the increase prevalence of cancer incidences. Furthermore, the increase in colloborations and partnerships among the pharmaceutical companies for the development of novel drugs in the management of cancer is going to boost the market. Despite this, there are several challenges such as their high manufacturing cost, limited oral bioavailability and low resistance to cleavage by serum proteases which restrain their growth in market.
In terms of revenus, North America is currently holding the top position and is expected to dominate the global peptide cancer market. This is mainly attributed to the region’s potency in healthcare and a strong presence of various peptide based cancer therapeutic drug manufacturers is supporting the growth of the market in North America. Moreover, the presence of top key players such as Novartis, AstraZenecea, Teva Pharmaceuticals and Pfizer also favours the growth of this region.
On the other hand, Asia Pacific is expected to register considerable growth over the forecast period owing to high untapped opportunities, low cost of raw material, growing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in the R&D sector. Cheaper cost of raw materials and patent expiration of blockbuster drugs boosting generic market is expected to provide significant growth opportunities shortly. In coming years, the cancer therapeutics market will witness increasing adoption of novel peptide therapeutics and will contribute to a major share in the overall market.
'Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026' report provides insights into the potential application of peptide therapeutics and their mode of action in the management of different cancers. In addition to this, the report also provide data on the pricing, sales and dosage of the currently available peptide based therapeutics and the robust clinical pipeline which are expected to enter the market in next coming years. Moreover, the various key players which are indulging in research activities for the development of novel peptides is also added in the report.
1. INTRODUCTION TO PEPTIDE THERAPEUTICS
1.1 Overview of Peptide Therapeutics
1.2 Historical Perspective of Peptide Therapeutics
1.3 Classification Of Anti Cancer Peptides
2. DESIGNING & FUNCTIONING OF PEPTIDE DRUGS
2.1 Rational Design Of Peptide Therapeutics
2.2 Approaches for Plasma Half Life Extension
2.3 Emerging Peptide Areas & Technologies
2.4 Peptide & Protein Interaction
3. SIGNIFICANCE OF PEPTIDES AS CANCER THERAPEUTICS
4. TARGETS FOR THERAPEUTIC PEPTIDES
4.1 Signal Transduction Pathways
4.2 Cell Cycle Regulation
4.3 Cell Death Pathways
4.4 Tumor Suppressor Protein
4.5 Transcription Factors
5. PEPTIDE DRUGS V/S CONVENTIONAL CANCER THERAPEUTICS
5.1 Peptide v/s Chemotherapy
5.2 Peptide v/s Monoclonal Antibody
5.3 Peptide v/s Gene Therapy
5.4 Peptide v/s Immunotherapy
6. DIFFERENT APPROACHES OF PEPTIDES IN CANCER THERAPEUTICS
6.1 Hormonal Peptides
6.2 Peptide as Radionuclide Drug Carrier
6.3 Peptide Vaccines
6.4 Peptides as Cytotoxic Drug Carrier
6.5 Anticancer Peptides
6.6 Other Anticancer Drugs Closely Related to Peptides
7. APPLICATION OF PEPTIDES THERAPEUTICS & DETECTION METHODOLOGY BY CANCER
7.1 Colorectal Cancer
7.2 Lung Cancer
7.3 Pancreatic Cancer
7.4 Gastric Cancer
7.5 Breast Cancer
7.6 Prostate Cancer
8. GLOBAL CANCER PEPTIDE THERAPEUTICS MARKET OVERVIEW: CURRENT SCENARIO
9. GLOBAL PEPTIDE CANCER THERAPEUTICS CLINICAL TRIALS OVERVIEW
9.1 By Company
9.2 By Country
9.3 By Indication
9.4 By Patient Segment
9.5 By Phase
9.6 By Drug Formulation
10. GLOBAL PEPTIDE CANCER THERAPEUTICS CLINICAL TRIALS INSIGHT
10.1 Unknown
10.2 Research
10.3 Preclinical
10.4 Phase I
10.5 Phase I/II
10.6 Phase II
10.7 Phase II/III
10.8 Phase III
10.9 Preregistration
10.10 Registered
11. MARKETED CANCER PEPTIDES CLINICAL INSIGHT BY COMPANY, COUNTRY & INDICATION
12. MARKETED CANCER PEPTIDES DRUGS INSIGHT – AVAILABILITY, COST, DOSAGE, INDICATION & PATENT INSIGHT
12.1 Firmagon (Degarelix)
12.2 Eligard (Leuprolide)
12.3 Lupron (Leuprolide Acetate)
12.4 Histrelin Acetate (Supprelin LA/Vantas)
12.5 Gonax (Degarelix Acetate)
12.6 Trelstar (Treptorelin)
12.7 Decapeptyl SR (Treptorelin Acetate or Pamoate)
12.8 Plenaxis (Abarelix)
12.9 Velcade (bortizomib)
12.10 Ninlaro (Ixazomib)
12.11 Kyprolis (Carfilzomib)
12.12 Romidepsin (Istodax)
12.13 PegIntron (PegInterferon alpha-2b)
12.14 Sylatron (Peginterferon Alpha-2b)
12.15 Zoladex (Goserelin)
12.16 Cosmegen (Dactinomycin)
12.17 Somatuline Depot (lanreotide)
12.18 Suprefact (Buserelin)
12.19 Octreotide (Generic)
12.20 Sandostatin (Octeriotide Acetate)
12.21 Bynfezia Pen (Octeriotide)
12.22 Mepact (Mifamurtide)
13. ROLE OF PEPTIDES IN CANCER IMMUNOTHERAPY
13.1 Overview
13.2 Peptide Vaccines for Immunotherapy
14. NEOANTIGEN VACCINE: AN EMERGING TUMOR IMMUNOTHERAPY
14.1 Personalized Neoantigen Based Vaccine in Cancer
14.2 Clinical Progress & Future Prospects
15. VENOM PEPTIDES: NEW ERA FOR CANCER PEPTIDE THERAPY
15.1 Relevance of Venom Based Peptide Therapeutics
15.2 Recent Clinical Trials & Future Growth Avenues of Venom Peptides
16. ADVANCEMENTS IN PEPTIDE ONCOLOGY DRUGS
17. GLOBAL PEPTIDE CANCER THERAPY MARKET DYNAMICS
17.1 Favorable Market Parameters
17.2 Commercialization Challenges
18. GLOBAL CANCER PEPTIDE THERAPEUTICS MARKET FUTURE OUTLOOK
19. COMPETITIVE LANDSCAPE
19.1 Novartis
19.2 Amgen
19.3 Eli - Lilly
19.4 Merck
19.5 Pfizer
19.6 GlaxoSmithKline plc
19.7 Ipsen
19.8 Lonza Inc.
19.9 Roche
19.10 Takeda Pharmaceuticals
19.11 Teva Pharmaceuticals
19.12 Novo Nordisk A/S
19.13 PolyPeptide Group
19.14 AstraZeneca plc
19.15 Bachem Holding AG
19.16 Ferring Pharmaceuticals
1.1 Overview of Peptide Therapeutics
1.2 Historical Perspective of Peptide Therapeutics
1.3 Classification Of Anti Cancer Peptides
2. DESIGNING & FUNCTIONING OF PEPTIDE DRUGS
2.1 Rational Design Of Peptide Therapeutics
2.2 Approaches for Plasma Half Life Extension
2.3 Emerging Peptide Areas & Technologies
2.4 Peptide & Protein Interaction
3. SIGNIFICANCE OF PEPTIDES AS CANCER THERAPEUTICS
4. TARGETS FOR THERAPEUTIC PEPTIDES
4.1 Signal Transduction Pathways
4.2 Cell Cycle Regulation
4.3 Cell Death Pathways
4.4 Tumor Suppressor Protein
4.5 Transcription Factors
5. PEPTIDE DRUGS V/S CONVENTIONAL CANCER THERAPEUTICS
5.1 Peptide v/s Chemotherapy
5.2 Peptide v/s Monoclonal Antibody
5.3 Peptide v/s Gene Therapy
5.4 Peptide v/s Immunotherapy
6. DIFFERENT APPROACHES OF PEPTIDES IN CANCER THERAPEUTICS
6.1 Hormonal Peptides
6.2 Peptide as Radionuclide Drug Carrier
6.3 Peptide Vaccines
6.4 Peptides as Cytotoxic Drug Carrier
6.5 Anticancer Peptides
6.6 Other Anticancer Drugs Closely Related to Peptides
7. APPLICATION OF PEPTIDES THERAPEUTICS & DETECTION METHODOLOGY BY CANCER
7.1 Colorectal Cancer
7.2 Lung Cancer
7.3 Pancreatic Cancer
7.4 Gastric Cancer
7.5 Breast Cancer
7.6 Prostate Cancer
8. GLOBAL CANCER PEPTIDE THERAPEUTICS MARKET OVERVIEW: CURRENT SCENARIO
9. GLOBAL PEPTIDE CANCER THERAPEUTICS CLINICAL TRIALS OVERVIEW
9.1 By Company
9.2 By Country
9.3 By Indication
9.4 By Patient Segment
9.5 By Phase
9.6 By Drug Formulation
10. GLOBAL PEPTIDE CANCER THERAPEUTICS CLINICAL TRIALS INSIGHT
10.1 Unknown
10.2 Research
10.3 Preclinical
10.4 Phase I
10.5 Phase I/II
10.6 Phase II
10.7 Phase II/III
10.8 Phase III
10.9 Preregistration
10.10 Registered
11. MARKETED CANCER PEPTIDES CLINICAL INSIGHT BY COMPANY, COUNTRY & INDICATION
12. MARKETED CANCER PEPTIDES DRUGS INSIGHT – AVAILABILITY, COST, DOSAGE, INDICATION & PATENT INSIGHT
12.1 Firmagon (Degarelix)
12.2 Eligard (Leuprolide)
12.3 Lupron (Leuprolide Acetate)
12.4 Histrelin Acetate (Supprelin LA/Vantas)
12.5 Gonax (Degarelix Acetate)
12.6 Trelstar (Treptorelin)
12.7 Decapeptyl SR (Treptorelin Acetate or Pamoate)
12.8 Plenaxis (Abarelix)
12.9 Velcade (bortizomib)
12.10 Ninlaro (Ixazomib)
12.11 Kyprolis (Carfilzomib)
12.12 Romidepsin (Istodax)
12.13 PegIntron (PegInterferon alpha-2b)
12.14 Sylatron (Peginterferon Alpha-2b)
12.15 Zoladex (Goserelin)
12.16 Cosmegen (Dactinomycin)
12.17 Somatuline Depot (lanreotide)
12.18 Suprefact (Buserelin)
12.19 Octreotide (Generic)
12.20 Sandostatin (Octeriotide Acetate)
12.21 Bynfezia Pen (Octeriotide)
12.22 Mepact (Mifamurtide)
13. ROLE OF PEPTIDES IN CANCER IMMUNOTHERAPY
13.1 Overview
13.2 Peptide Vaccines for Immunotherapy
14. NEOANTIGEN VACCINE: AN EMERGING TUMOR IMMUNOTHERAPY
14.1 Personalized Neoantigen Based Vaccine in Cancer
14.2 Clinical Progress & Future Prospects
15. VENOM PEPTIDES: NEW ERA FOR CANCER PEPTIDE THERAPY
15.1 Relevance of Venom Based Peptide Therapeutics
15.2 Recent Clinical Trials & Future Growth Avenues of Venom Peptides
16. ADVANCEMENTS IN PEPTIDE ONCOLOGY DRUGS
17. GLOBAL PEPTIDE CANCER THERAPY MARKET DYNAMICS
17.1 Favorable Market Parameters
17.2 Commercialization Challenges
18. GLOBAL CANCER PEPTIDE THERAPEUTICS MARKET FUTURE OUTLOOK
19. COMPETITIVE LANDSCAPE
19.1 Novartis
19.2 Amgen
19.3 Eli - Lilly
19.4 Merck
19.5 Pfizer
19.6 GlaxoSmithKline plc
19.7 Ipsen
19.8 Lonza Inc.
19.9 Roche
19.10 Takeda Pharmaceuticals
19.11 Teva Pharmaceuticals
19.12 Novo Nordisk A/S
19.13 PolyPeptide Group
19.14 AstraZeneca plc
19.15 Bachem Holding AG
19.16 Ferring Pharmaceuticals
LIST OF FIGURES
Figure 1-1: Classification of Anti-Cancer Peptides
Figure 2-1: Traditional Structure-Based Design Strategies Used in Peptide Drug Discovery
Figure 3-1: Significance of Peptides as Cancer Therapeutics
Figure 3-2: US - Per Unit Cost of Cancer Drug (US$)
Figure 4-1: Therapeutic Peptides Based on Their Biological Targets
Figure 4-2: MAPK Signaling Pathways
Figure 4-3: Cell Cycle in Eukaryotic
Figure 4-4: Cell Death Pathways
Figure 4-5: Features of Bcl-2 Family Proteins Including Anti-Apoptotic & Pro-Apoptotic
Figure 5-1: Limitations of Monoclonal Antibody
Figure 5-2: Monoclonal Antibodies & Peptide Therapeutics – Cost of Production per gram (US$)
Figure 5-3: Pre-Requisite for Gene Therapy
Figure 5-4: Limitations of Gene Therapy
Figure 5-5: Drawbacks of Immunotherapy
Figure 6-1: Different Approaches of Peptide in Cancer Management
Figure 6-2: Mode of Action – LHRH Agonist & LHRH Antagonist
Figure 6-3: Effects of Somatostatin Analogs
Figure 6-4: Peptide Receptor Radionuclide Therapy
Figure 6-5: Mechanism of Peptide Vaccines
Figure 6-6: Peptides in Clinical Trials
Figure 7-1: Peptides & their Targets in CRC
Figure 7-2: Peptides Undergoing Clinical Trials in CRC
Figure 7-3: Peptides in Treatment of Lung Cancer
Figure 7-4: Antigens Utilized as Molecular Targets
Figure 7-5: Peptide Based Vaccines in Clinical Development
Figure 7-6: Peptide Vaccine in Breast Cancer
Figure 8-1: Global – Peptide Therapeutic Market Size (US$ Billion), 2018 - 2026
Figure 8-2: Global – Total Peptide Therapeutic Market Size vs. Oncological Peptide Therapeutic Market Size (US$ Billion), 2019
Figure 8-3: Global – Oncological Peptide Therapeutics Market Share in Total Peptide market (%), 2019
Figure 8-4: Global – Peptide Oncology Drugs Market Size (US$ Billion), 2018 - 2026
Figure 8-5: Peptide Oncology Market – Regional Market Share (%), 2019
Figure 9-1: Global - Peptide Cancer Drug Clinical Pipeline by Company (Number of Drugs), 2021 till 2026
Figure 9-2: Global - Peptide Cancer Drug Clinical Pipeline by Country (Number of Drugs), 2021 till 2026
Figure 9-3: Global - Peptide Cancer Drug Clinical Pipeline by Indication (Number of Drugs), 2021 till 2026
Figure 9-4: Global - Peptide Cancer Drug Clinical Pipeline by Patient Segment (Number of Drugs), 2021 till 2026
Figure 9-5: Global - Peptide Cancer Drug Clinical Pipeline by Phase (Number of Drugs), 2021 till 2026
Figure 9-6: Global - Peptide Cancer Drug Clinical Pipeline by Drug Formulation (Number of Drugs), 2021 till 2026
Figure 12-1: Frimagon – Years of Different Patent Issue
Figure 12-2: Frimagon – Expiration Year of Different Patents
Figure 12-3: Frimagon – Price for Single Supply of 80mg & 120mg Powder for Subcutaneous Injection (US$), March’2021
Figure 12-4: Firmagon - Starting & Maintenance Dosage (mg)
Figure 12-5: Firmagon – Treatment Cost of Initial Cycle, Maintenance Cycle & Annual Treatment Cost (US$), March’2021
Figure 12-6: Eligard - Cost of Different doses of Extended Release Subcutaneous Powder for Injection (US$), March’2021
Figure 12-7: Eligard – Recommended Dosage for Prostate Cancer on Monthly Basis (mg)
Figure 12-8: Eligard – Annual Treatment cost of Prostate Cancer using Different available Doses (US$), March’2021
Figure 12-9: Eligard – Recommended Dose for Treatment of Uterine Leiomyomata on Monthly Basis (mg), March’2021
Figure 12-10: Eligard – Cost per Month & Full Treatment Cost of Uterine Leiomyomata using 7.5mg Dose (US$), March’2021
Figure 12-11: Lupron – Patent Issue & Expiration Year for Controlled Release Preparation
Figure 12-12: Lupron – Patent Issue & Expiration Year for Sustained Release Preparation
Figure 12-13: Lupron – Price for 7.5mg, 22.5mg, 30mg & 40mg Depot (US$), March’2021
Figure 12-14: Lupron – Price for 3.75 mg & 11.25 mg Supply of Intramuscular Powder for Injection (US$), March’2021
Figure 12-15: Lupron – Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)
Figure 12-16: Lupron – Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), March’2021
Figure 12-17: Lupron – Recommended Dose for Treatment of Uterine Leiomyomata on Monthly Basis (mg), March’2021
Figure 12-18: Lupron – Cost per Month & Full Treatment Cost of Uterine Leiomyomata using 3.75mg Depot (US$), January’201
Figure 12-19: Histrelin – FDA approval Year by Brand Name
Figure 12-20: Supprelin LA – FDA Approval Year by Brand Name
Figure 12-21: Histrelin – Price for Single 50mg Implant by Brand Name (US$), March’2021
Figure 12-22: Gonax - Cost of 80mg & 120mg Supply of Powder for Subcutaneous Injection (US$), March’2021
Figure 12-23: Gonax - Starting & Maintenance Dosage (mg)
Figure 12-24: Gonax – Treatment Cost of Initial Month, Maintenance Month & Annually (US$), March’2021
Figure 12-25: Trelstar – Patent Issue & Expiration Year
Figure 12-26: Trelstar - Cost for a Supply of 3.75mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), March’2021
Figure 12-27: Trelstar - Recommended Dose for Prostate Cancer Treatment (mg), March’2021
Figure 12-28: Trelstar – Annual Treatment Cost using 3.75 mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), March’2021
Figure 12-29: Decapeptyl SR – Price for a Supply of 3mg, 11.25mg & 22.5mg Powder for Injection (GBP/US$), March’2021
Figure 12-30: Decapeptyl SR - Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)
Figure 12-31: Decapeptyl SR - Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), March’2021
Figure 12-32: Global – Decapeptyl Annual Sales (Euro/US$ Million), 2018-2020
Figure 12-33: Global – Decapeptyl Quarterly Sales (Euro/US$ Million), 2019
Figure 12-34: Global – Decapeptyl Quarterly Sales (Euro/US$ Million), 2020
Figure 12-35: Plenaxis – Number of Recommended Doses on Monthly Basis
Figure 12-36: Velcade – 1st & 2nd Patent Issue & Expiration Year
Figure 12-37: Velcade – Minimum & Maximum Cost of Single Treatment Cycle (US$), March’2021
Figure 12-38: Velcade – Minimum & Maximum Cost of Single Treatment Cycle (US$), March’2021
Figure 12-39: Global – Velcade Sales Value (JPY/US$ Billion), 2017 - 2020
Figure 12-40: US – Velcade Sales Value (JPY/US$ Billion), 2018 & 2019
Figure 12-41: Global – Velcade Sales Value by Region (%), 2019
Figure 12-42: Global – Velcade Quarterly Sales Value (JPY/US$ Billion), Q1 & Q2, 2020
Figure 12-43: Ninlaro – Patent Issue & Expiration Year
Figure 12-44: Ninlaro – Price for 3 Capsule Supply & Price per Unit of Ninlaro Capsule (US$), March’2021
Figure 12-45: Ninlaro – Recommended Dose & Dose Reductions for Treatment of Multiple Myeloma (Mg/Week), March’2021
Figure 12-46: Ninlaro – Cost of 1 Treatment Cycle & Annual Treatment Cost for Multiple Myeloma (US$), March’2021
Figure 12-47: Ninlaro – Annual Sales Value (JPY/US$ Billion), 2018-2020
Figure 12-48: Ninlaro – Annual Sales by Region (%), 2019
Figure 12-49: Global – Ninlaro Quarterly Sales Value (JPY/US$ Billion), Q1-Q3, 2020
Figure 12-50: Kyprolis – Proteolix Inc’s Patents Issue & Expiration Year
Figure 12-51: Kyprolis – Cydex Pharmaceutical’s Patent Issue & Expiration Year
Figure 12-52: Kyprolis – Issue & Expiration Year of Patents Assigned to Onyx Therapeutics
Figure 12-53: Kyprolis – Price of 10mg, 30mg & 60mg Intravenous Powder for Injection (US$), March’2021
Figure 12-54: Kyprolis – Initial Dose & Maintenance Dose for Treatment of Multiple Myeloma (mg/m2 Per Week)
Figure 12-55: Kyprolis - Initial Dose & Maintenance Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m2 Twice a Week)
Figure 12-56: Kyprolis – Annual Sales Value (US$ Million), 2018-2020
Figure 12-57: Kyprolis – Annual Sales by Region (%), 2020
Figure 12-58: Global - Kyprolis Quarterly Sales Value (US$ Million), Q1 – Q4, 2020
Figure 12-59: US - Kyprolis Quarterly Sales Value (US$ Million), Q1-Q4, 2020
Figure 12-60: Romidepsin – FDA Approval Year by Indication
Figure 12-61: Romidepsin – Price for a Supply of 10mg Branded & Generic Intravenous Powder (US$), March’2021
Figure 12-62: Romidepsin Intravenous Solution – Price for 5.5ml Supply & Price per ml of 5mg/ml Solution (US$), March’2021
Figure 12-63: Istodax – Cost of Single Dose & Single Treatment cycle (US$), March’2021
Figure 12-64: PegIntron - Patent Expiration Year by Region
Figure 12-65: PegIntron – Price for 4 Powder Supply & Price Per Unit of 120mg Powder for Injection (US$), March’2021
Figure 12-66: PegIntron Monotherapy – Dose by Weight of Patient (mcg), March’2021
Figure 12-67: PegIntron Monotherapy – Reduced Dose by Weight of Patient (mcg), March’2021
Figure 12-68: Pegintron Combination – Duration of Treatment by Genotype (Weeks), March’2021
Figure 12-69: Sylatron – Price for 4 Powder Supply & Price per Unit of 120mg Powder for Injection (US$), March’2021
Figure 12-70: Sylatron – Initial & Maintenance Dose (mcg/Kg/Week), March’2021
Figure 12-71: Sylatron – Duration of Initial Phase, Maintenance Phase & Full Treatment (Weeks), March’2021
Figure 12-72: Sylatron - Average Cost of Single Initial Dose & Full Initial Phase (US$), March’2021
Figure 12-73: Sylatron - Average Cost of Single Maintenance Dose, Annual Maintenance Cost & Full Maintenance Phase (US$), January’2020
Figure 12-74: Zoladex – Patent Issue & Expiration Year
Figure 12-75: Zoladex - Cost of 3.6mg & 10.8mg Implant (US$), March’2021
Figure 12-76: Zoladex – Recommended Dose for Prostate cancer Management on Monthly Basis (MG), March’2021
Figure 12-77: Zoladex – Annual Treatment Cost using 3.6mg & 10.8mg Implant (US$), March’2021
Figure 12-78: Global - Zoladex Annual Sales Value (US$ Million), 2017 - 2020
Figure 12-79: Zoladex – Annual Sales by Region (US$ Million), 2020
Figure 12-80: Zoladex – Annual Sales by Region (%), 2020
Figure 12-81: US - Zoladex Annual Sales Value (US$ Million), 2017 - 2019
Figure 12-82: Europe - Zoladex Annual Sales Value (US$ Million), 2017 - 2020
Figure 12-83: Zoladex – Quarterly Sales Value (US$ Million), Q1 – Q4, 2020
Figure 12-84: Dactinomycin – Price for Generic & Branded 0.5mg Powder for Injection (US$), March’2021
Figure 12-85: Cosmegen – Average Cost of Treatment for Wilm’s Tumor (US$), March’2021
Figure 12-86: Cosmegen – Average Cost of One Cycle & Full Treatment Cost For Rhabdomyosarcoma (US$), March’2021
Figure 12-87: Cosmegen – Cost of One Cycle & Full Treatment Cost for Ewing’s Tumor (US$), March’2021
Figure 12-88: Cosmegen – Treatment Cost of One Cycle & Full Treatment Cost of Testicular Cancer (US$), March’2021
Figure 12-89: Cosmegen – Full Treatment Cost as Monotherapy & Combinational Therapy in Trophoblastic Disease (US$), March’2021
Figure 12-90: Cosmegen – Full Treatment Cost of Upper & lower Body Solid Tumor (US$), March’2021
Figure 12-91: Somatuline Depot – Price of 60mg/0.2 ml Supply & Price per ml of Somatulin Depot Subcutaneous Solution (US$), March’2021
Figure 12-92: Somatuline Depot – Price of 90mg/0.3ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), March’2021
Figure 12-93: Somatuline Depot – Price of 120mg/0.5ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), March’2021
Figure 12-94: Somatuline Depot – Treatment cost of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US$), March’2021
Figure 12-95: Global – Somatuline Annual Sales (Euro/US$ Million), 2018-2020
Figure 12-96: Global – Somatuline Quarterly Sales (Euro/US$ Million), 2019
Figure 12-97: Global – Somatuline Quarterly Sales (Euro/US$ Million), 2020
Figure 12-98: Suprefact – Price of 6.3mg & 9.45mg Depot (US$), March’2021
Figure 12-99: Suprefact – Cost for a Supply of 1ml/ml Nasal Spray & Injectable solution (US$), March’2021
Figure 12-100: Suprefact Injection – Recommended Initial Dose & Final Dose for Prostate Cancer Treatment (mg/Day), March’2021
Figure 12-101: Suprefact Depot – Recommended Dose for Prostate Cancer Treatment on Monthly Basis (mg), March’2021
Figure 12-102: Suprefact Depot – Annual Prostate Cancer Treatment Cost (US$), March’2021
Figure 12-103: Octreotide - Cost of 10ml Supplies of Various Dose Regimens (US$), March’2021
Figure 12-104: Octreotide – Average Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg), Janaury’2021
Figure 12-105: Sandostatin – Price for 10 Vial Supply & per Unit Price of 50mcg/ml Injectable Solution (US$), March’2021
Figure 12-106: Sandostatin – Price for 10 Vial Supply & per Unit Price of 100mcg/ml Injectable Solution (US$), March’2021
Figure 12-107: Sandostatin – Price for 10 Vial Supply & per Unit Price of 500mcg/ml Injectable Solution (US$), March’2021
Figure 12-108: Sandostatin LAR – Price for Various Supplies of Intramuscular Powder for Injection, March’2021
Figure 12-109: Sandostatin - Mean Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg), March’2021
Figure 12-110: Global - Sandostatin Annual Sales Value (US$ Million), 2018-2020
Figure 12-111: Global – Sandostatin Quarter Sales Value (US$ Million),2020
Figure 12-112: Bynfezia Pen – Patent Issue & Expiration Year
Figure 12-113: Bynfezia Pen – Price for 2.8ml Supply & Price per ml of 2500mcg/ml Subcutaneous Solution (US$), Januar’2021
Figure 12-114: Bynfezia Pen – Price for 5.6ml Supply & Price per ml of 2500mcg/ml Subcutaneous Solution (US$), Januar’2021
Figure 12-115: Bynfezia Pen – Mean Dose for First 2 Week & Subsequent Weeks (mcg/day)
Figure 12-116: Mepact - Recommended Number of Dose Administration/ Week for 12 & 24 Weeks Treatment
Figure 12-117: Germany – Cost of Single Dose & Full Treatment (EUR/US$), March’2021
Figure 13-1: Role of Peptides in Cancer Immunotherapy
Figure 14-1: Benefits of Neoantigens
Figure 14-2: Steps of Producing Neoantigen Vaccine
Figure 14-3: Neoantigen Vaccine - Mode of Action
Figure 14-4: Neoantigen Vaccine in Clinical Development
Figure 15-1: Advantages of Venom Peptides
Figure 15-2: Other Venom Peptides in Cancer Therapy
Figure 15-3: Venom Peptides in Clinical Pipeline
Figure 16-1: Mechanism of Action of the BC71 Peptide by Targeting Cell-Surface GRP78 in Cancer
Figure 17-1: Favorable Market Parameters
Figure 17-2: Commercialization Challenges
Figure 18-1: Global – Somatostatin Analogues Market Size (US$ Million), 2020 - 2024
Figure 18-2: Clinical Timeline of Therapeutic Peptides
Figure 1-1: Classification of Anti-Cancer Peptides
Figure 2-1: Traditional Structure-Based Design Strategies Used in Peptide Drug Discovery
Figure 3-1: Significance of Peptides as Cancer Therapeutics
Figure 3-2: US - Per Unit Cost of Cancer Drug (US$)
Figure 4-1: Therapeutic Peptides Based on Their Biological Targets
Figure 4-2: MAPK Signaling Pathways
Figure 4-3: Cell Cycle in Eukaryotic
Figure 4-4: Cell Death Pathways
Figure 4-5: Features of Bcl-2 Family Proteins Including Anti-Apoptotic & Pro-Apoptotic
Figure 5-1: Limitations of Monoclonal Antibody
Figure 5-2: Monoclonal Antibodies & Peptide Therapeutics – Cost of Production per gram (US$)
Figure 5-3: Pre-Requisite for Gene Therapy
Figure 5-4: Limitations of Gene Therapy
Figure 5-5: Drawbacks of Immunotherapy
Figure 6-1: Different Approaches of Peptide in Cancer Management
Figure 6-2: Mode of Action – LHRH Agonist & LHRH Antagonist
Figure 6-3: Effects of Somatostatin Analogs
Figure 6-4: Peptide Receptor Radionuclide Therapy
Figure 6-5: Mechanism of Peptide Vaccines
Figure 6-6: Peptides in Clinical Trials
Figure 7-1: Peptides & their Targets in CRC
Figure 7-2: Peptides Undergoing Clinical Trials in CRC
Figure 7-3: Peptides in Treatment of Lung Cancer
Figure 7-4: Antigens Utilized as Molecular Targets
Figure 7-5: Peptide Based Vaccines in Clinical Development
Figure 7-6: Peptide Vaccine in Breast Cancer
Figure 8-1: Global – Peptide Therapeutic Market Size (US$ Billion), 2018 - 2026
Figure 8-2: Global – Total Peptide Therapeutic Market Size vs. Oncological Peptide Therapeutic Market Size (US$ Billion), 2019
Figure 8-3: Global – Oncological Peptide Therapeutics Market Share in Total Peptide market (%), 2019
Figure 8-4: Global – Peptide Oncology Drugs Market Size (US$ Billion), 2018 - 2026
Figure 8-5: Peptide Oncology Market – Regional Market Share (%), 2019
Figure 9-1: Global - Peptide Cancer Drug Clinical Pipeline by Company (Number of Drugs), 2021 till 2026
Figure 9-2: Global - Peptide Cancer Drug Clinical Pipeline by Country (Number of Drugs), 2021 till 2026
Figure 9-3: Global - Peptide Cancer Drug Clinical Pipeline by Indication (Number of Drugs), 2021 till 2026
Figure 9-4: Global - Peptide Cancer Drug Clinical Pipeline by Patient Segment (Number of Drugs), 2021 till 2026
Figure 9-5: Global - Peptide Cancer Drug Clinical Pipeline by Phase (Number of Drugs), 2021 till 2026
Figure 9-6: Global - Peptide Cancer Drug Clinical Pipeline by Drug Formulation (Number of Drugs), 2021 till 2026
Figure 12-1: Frimagon – Years of Different Patent Issue
Figure 12-2: Frimagon – Expiration Year of Different Patents
Figure 12-3: Frimagon – Price for Single Supply of 80mg & 120mg Powder for Subcutaneous Injection (US$), March’2021
Figure 12-4: Firmagon - Starting & Maintenance Dosage (mg)
Figure 12-5: Firmagon – Treatment Cost of Initial Cycle, Maintenance Cycle & Annual Treatment Cost (US$), March’2021
Figure 12-6: Eligard - Cost of Different doses of Extended Release Subcutaneous Powder for Injection (US$), March’2021
Figure 12-7: Eligard – Recommended Dosage for Prostate Cancer on Monthly Basis (mg)
Figure 12-8: Eligard – Annual Treatment cost of Prostate Cancer using Different available Doses (US$), March’2021
Figure 12-9: Eligard – Recommended Dose for Treatment of Uterine Leiomyomata on Monthly Basis (mg), March’2021
Figure 12-10: Eligard – Cost per Month & Full Treatment Cost of Uterine Leiomyomata using 7.5mg Dose (US$), March’2021
Figure 12-11: Lupron – Patent Issue & Expiration Year for Controlled Release Preparation
Figure 12-12: Lupron – Patent Issue & Expiration Year for Sustained Release Preparation
Figure 12-13: Lupron – Price for 7.5mg, 22.5mg, 30mg & 40mg Depot (US$), March’2021
Figure 12-14: Lupron – Price for 3.75 mg & 11.25 mg Supply of Intramuscular Powder for Injection (US$), March’2021
Figure 12-15: Lupron – Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)
Figure 12-16: Lupron – Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), March’2021
Figure 12-17: Lupron – Recommended Dose for Treatment of Uterine Leiomyomata on Monthly Basis (mg), March’2021
Figure 12-18: Lupron – Cost per Month & Full Treatment Cost of Uterine Leiomyomata using 3.75mg Depot (US$), January’201
Figure 12-19: Histrelin – FDA approval Year by Brand Name
Figure 12-20: Supprelin LA – FDA Approval Year by Brand Name
Figure 12-21: Histrelin – Price for Single 50mg Implant by Brand Name (US$), March’2021
Figure 12-22: Gonax - Cost of 80mg & 120mg Supply of Powder for Subcutaneous Injection (US$), March’2021
Figure 12-23: Gonax - Starting & Maintenance Dosage (mg)
Figure 12-24: Gonax – Treatment Cost of Initial Month, Maintenance Month & Annually (US$), March’2021
Figure 12-25: Trelstar – Patent Issue & Expiration Year
Figure 12-26: Trelstar - Cost for a Supply of 3.75mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), March’2021
Figure 12-27: Trelstar - Recommended Dose for Prostate Cancer Treatment (mg), March’2021
Figure 12-28: Trelstar – Annual Treatment Cost using 3.75 mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), March’2021
Figure 12-29: Decapeptyl SR – Price for a Supply of 3mg, 11.25mg & 22.5mg Powder for Injection (GBP/US$), March’2021
Figure 12-30: Decapeptyl SR - Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)
Figure 12-31: Decapeptyl SR - Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), March’2021
Figure 12-32: Global – Decapeptyl Annual Sales (Euro/US$ Million), 2018-2020
Figure 12-33: Global – Decapeptyl Quarterly Sales (Euro/US$ Million), 2019
Figure 12-34: Global – Decapeptyl Quarterly Sales (Euro/US$ Million), 2020
Figure 12-35: Plenaxis – Number of Recommended Doses on Monthly Basis
Figure 12-36: Velcade – 1st & 2nd Patent Issue & Expiration Year
Figure 12-37: Velcade – Minimum & Maximum Cost of Single Treatment Cycle (US$), March’2021
Figure 12-38: Velcade – Minimum & Maximum Cost of Single Treatment Cycle (US$), March’2021
Figure 12-39: Global – Velcade Sales Value (JPY/US$ Billion), 2017 - 2020
Figure 12-40: US – Velcade Sales Value (JPY/US$ Billion), 2018 & 2019
Figure 12-41: Global – Velcade Sales Value by Region (%), 2019
Figure 12-42: Global – Velcade Quarterly Sales Value (JPY/US$ Billion), Q1 & Q2, 2020
Figure 12-43: Ninlaro – Patent Issue & Expiration Year
Figure 12-44: Ninlaro – Price for 3 Capsule Supply & Price per Unit of Ninlaro Capsule (US$), March’2021
Figure 12-45: Ninlaro – Recommended Dose & Dose Reductions for Treatment of Multiple Myeloma (Mg/Week), March’2021
Figure 12-46: Ninlaro – Cost of 1 Treatment Cycle & Annual Treatment Cost for Multiple Myeloma (US$), March’2021
Figure 12-47: Ninlaro – Annual Sales Value (JPY/US$ Billion), 2018-2020
Figure 12-48: Ninlaro – Annual Sales by Region (%), 2019
Figure 12-49: Global – Ninlaro Quarterly Sales Value (JPY/US$ Billion), Q1-Q3, 2020
Figure 12-50: Kyprolis – Proteolix Inc’s Patents Issue & Expiration Year
Figure 12-51: Kyprolis – Cydex Pharmaceutical’s Patent Issue & Expiration Year
Figure 12-52: Kyprolis – Issue & Expiration Year of Patents Assigned to Onyx Therapeutics
Figure 12-53: Kyprolis – Price of 10mg, 30mg & 60mg Intravenous Powder for Injection (US$), March’2021
Figure 12-54: Kyprolis – Initial Dose & Maintenance Dose for Treatment of Multiple Myeloma (mg/m2 Per Week)
Figure 12-55: Kyprolis - Initial Dose & Maintenance Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m2 Twice a Week)
Figure 12-56: Kyprolis – Annual Sales Value (US$ Million), 2018-2020
Figure 12-57: Kyprolis – Annual Sales by Region (%), 2020
Figure 12-58: Global - Kyprolis Quarterly Sales Value (US$ Million), Q1 – Q4, 2020
Figure 12-59: US - Kyprolis Quarterly Sales Value (US$ Million), Q1-Q4, 2020
Figure 12-60: Romidepsin – FDA Approval Year by Indication
Figure 12-61: Romidepsin – Price for a Supply of 10mg Branded & Generic Intravenous Powder (US$), March’2021
Figure 12-62: Romidepsin Intravenous Solution – Price for 5.5ml Supply & Price per ml of 5mg/ml Solution (US$), March’2021
Figure 12-63: Istodax – Cost of Single Dose & Single Treatment cycle (US$), March’2021
Figure 12-64: PegIntron - Patent Expiration Year by Region
Figure 12-65: PegIntron – Price for 4 Powder Supply & Price Per Unit of 120mg Powder for Injection (US$), March’2021
Figure 12-66: PegIntron Monotherapy – Dose by Weight of Patient (mcg), March’2021
Figure 12-67: PegIntron Monotherapy – Reduced Dose by Weight of Patient (mcg), March’2021
Figure 12-68: Pegintron Combination – Duration of Treatment by Genotype (Weeks), March’2021
Figure 12-69: Sylatron – Price for 4 Powder Supply & Price per Unit of 120mg Powder for Injection (US$), March’2021
Figure 12-70: Sylatron – Initial & Maintenance Dose (mcg/Kg/Week), March’2021
Figure 12-71: Sylatron – Duration of Initial Phase, Maintenance Phase & Full Treatment (Weeks), March’2021
Figure 12-72: Sylatron - Average Cost of Single Initial Dose & Full Initial Phase (US$), March’2021
Figure 12-73: Sylatron - Average Cost of Single Maintenance Dose, Annual Maintenance Cost & Full Maintenance Phase (US$), January’2020
Figure 12-74: Zoladex – Patent Issue & Expiration Year
Figure 12-75: Zoladex - Cost of 3.6mg & 10.8mg Implant (US$), March’2021
Figure 12-76: Zoladex – Recommended Dose for Prostate cancer Management on Monthly Basis (MG), March’2021
Figure 12-77: Zoladex – Annual Treatment Cost using 3.6mg & 10.8mg Implant (US$), March’2021
Figure 12-78: Global - Zoladex Annual Sales Value (US$ Million), 2017 - 2020
Figure 12-79: Zoladex – Annual Sales by Region (US$ Million), 2020
Figure 12-80: Zoladex – Annual Sales by Region (%), 2020
Figure 12-81: US - Zoladex Annual Sales Value (US$ Million), 2017 - 2019
Figure 12-82: Europe - Zoladex Annual Sales Value (US$ Million), 2017 - 2020
Figure 12-83: Zoladex – Quarterly Sales Value (US$ Million), Q1 – Q4, 2020
Figure 12-84: Dactinomycin – Price for Generic & Branded 0.5mg Powder for Injection (US$), March’2021
Figure 12-85: Cosmegen – Average Cost of Treatment for Wilm’s Tumor (US$), March’2021
Figure 12-86: Cosmegen – Average Cost of One Cycle & Full Treatment Cost For Rhabdomyosarcoma (US$), March’2021
Figure 12-87: Cosmegen – Cost of One Cycle & Full Treatment Cost for Ewing’s Tumor (US$), March’2021
Figure 12-88: Cosmegen – Treatment Cost of One Cycle & Full Treatment Cost of Testicular Cancer (US$), March’2021
Figure 12-89: Cosmegen – Full Treatment Cost as Monotherapy & Combinational Therapy in Trophoblastic Disease (US$), March’2021
Figure 12-90: Cosmegen – Full Treatment Cost of Upper & lower Body Solid Tumor (US$), March’2021
Figure 12-91: Somatuline Depot – Price of 60mg/0.2 ml Supply & Price per ml of Somatulin Depot Subcutaneous Solution (US$), March’2021
Figure 12-92: Somatuline Depot – Price of 90mg/0.3ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), March’2021
Figure 12-93: Somatuline Depot – Price of 120mg/0.5ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), March’2021
Figure 12-94: Somatuline Depot – Treatment cost of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US$), March’2021
Figure 12-95: Global – Somatuline Annual Sales (Euro/US$ Million), 2018-2020
Figure 12-96: Global – Somatuline Quarterly Sales (Euro/US$ Million), 2019
Figure 12-97: Global – Somatuline Quarterly Sales (Euro/US$ Million), 2020
Figure 12-98: Suprefact – Price of 6.3mg & 9.45mg Depot (US$), March’2021
Figure 12-99: Suprefact – Cost for a Supply of 1ml/ml Nasal Spray & Injectable solution (US$), March’2021
Figure 12-100: Suprefact Injection – Recommended Initial Dose & Final Dose for Prostate Cancer Treatment (mg/Day), March’2021
Figure 12-101: Suprefact Depot – Recommended Dose for Prostate Cancer Treatment on Monthly Basis (mg), March’2021
Figure 12-102: Suprefact Depot – Annual Prostate Cancer Treatment Cost (US$), March’2021
Figure 12-103: Octreotide - Cost of 10ml Supplies of Various Dose Regimens (US$), March’2021
Figure 12-104: Octreotide – Average Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg), Janaury’2021
Figure 12-105: Sandostatin – Price for 10 Vial Supply & per Unit Price of 50mcg/ml Injectable Solution (US$), March’2021
Figure 12-106: Sandostatin – Price for 10 Vial Supply & per Unit Price of 100mcg/ml Injectable Solution (US$), March’2021
Figure 12-107: Sandostatin – Price for 10 Vial Supply & per Unit Price of 500mcg/ml Injectable Solution (US$), March’2021
Figure 12-108: Sandostatin LAR – Price for Various Supplies of Intramuscular Powder for Injection, March’2021
Figure 12-109: Sandostatin - Mean Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg), March’2021
Figure 12-110: Global - Sandostatin Annual Sales Value (US$ Million), 2018-2020
Figure 12-111: Global – Sandostatin Quarter Sales Value (US$ Million),2020
Figure 12-112: Bynfezia Pen – Patent Issue & Expiration Year
Figure 12-113: Bynfezia Pen – Price for 2.8ml Supply & Price per ml of 2500mcg/ml Subcutaneous Solution (US$), Januar’2021
Figure 12-114: Bynfezia Pen – Price for 5.6ml Supply & Price per ml of 2500mcg/ml Subcutaneous Solution (US$), Januar’2021
Figure 12-115: Bynfezia Pen – Mean Dose for First 2 Week & Subsequent Weeks (mcg/day)
Figure 12-116: Mepact - Recommended Number of Dose Administration/ Week for 12 & 24 Weeks Treatment
Figure 12-117: Germany – Cost of Single Dose & Full Treatment (EUR/US$), March’2021
Figure 13-1: Role of Peptides in Cancer Immunotherapy
Figure 14-1: Benefits of Neoantigens
Figure 14-2: Steps of Producing Neoantigen Vaccine
Figure 14-3: Neoantigen Vaccine - Mode of Action
Figure 14-4: Neoantigen Vaccine in Clinical Development
Figure 15-1: Advantages of Venom Peptides
Figure 15-2: Other Venom Peptides in Cancer Therapy
Figure 15-3: Venom Peptides in Clinical Pipeline
Figure 16-1: Mechanism of Action of the BC71 Peptide by Targeting Cell-Surface GRP78 in Cancer
Figure 17-1: Favorable Market Parameters
Figure 17-2: Commercialization Challenges
Figure 18-1: Global – Somatostatin Analogues Market Size (US$ Million), 2020 - 2024
Figure 18-2: Clinical Timeline of Therapeutic Peptides
